DBVT
HealthcareDBV Technologies S.A.
$16.99
$-2.06 (-10.81%)
Jan 5, 2026
Price History (1Y)
Analysis
DBV Technologies S.A. is a biotechnology company operating in the healthcare sector, with a market capitalization of $681.87 million and 117 employees. The company's revenue has grown by 158.8% year-over-year, reaching $5.50 million on a trailing twelve-month basis. The financial health of DBV Technologies S.A. is characterized by significant net losses, with a net income of -$125,133,000 on a trailing twelve-month basis. The company's gross margin stands at 100.0%, while its operating and profit margins are -1235.7% and 0.0%, respectively. In terms of returns, the return on equity is -234.1%, and the return on assets is -77.3%. On the balance sheet, DBV Technologies S.A. has a cash position of $69.84 million and debt of $7.69 million, resulting in a debt-to-equity ratio of 14.55. The valuation context for DBV Technologies S.A. is marked by a negative forward P/E ratio of -31.37, indicating significant losses relative to its market capitalization. The price-to-book ratio stands at 44.02, and the price-to-sales ratio is 123.93.
This analysis is AI-generated for informational purposes only and should not be considered financial advice. Data may be delayed or inaccurate. Always do your own research and consult a qualified financial advisor before making investment decisions.
About DBV Technologies S.A.
DBV Technologies S.A., a clinical-stage biopharmaceutical company, engages in the research and development of epicutaneous immunotherapy products in France. The company's product pipeline comprising Viaskin Peanut, an immunotherapy product, which has completed Phase 3 clinical trial for the treatment of peanut allergies; and Viaskin Milk which is in Phase 1/2 clinical trial for the treatment of immunoglobulin E (IgE) mediated or cow's milk protein allergy and eosinophilic esophagitis. Its earlier stage research programs include vaccine for the respiratory syncytial virus, potential treatments for inflammatory bowel disease, celiac disease, and type I diabetes. In addition, the company develops Viaskin technology platform, a platform to potentially treat food allergy. It has a collaboration with Nestlé Health Science to develop MAG1C, a ready-to-use atopy patch test for the diagnosis of non-IgE mediated CMPA in infants and toddlers. DBV Technologies S.A. was incorporated in 2002 and is headquartered in Châtillon, France.
Visit website →Key Statistics
- Market Cap
- $681.87M
- P/E Ratio
- N/A
- 52-Week High
- $26.18
- 52-Week Low
- $3.33
- Avg Volume
- 378.10K
- Beta
- -0.41
Company Info
- Industry
- Biotechnology
- Exchange
- NCM
- Country
- France
- Employees
- 117